STRATEGIC CLINICAL INNOVATION ORGANIZATION (SCIO)
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

STRATEGIC CLINICAL INNOVATION ORGANIZATION (SCIO) Trademark

Serial Number: 97163869 • Registration: 7210095

STRATEGIC CLINICAL INNOVATION ORGANIZATION (SCIO) is a trademark filed by Boston Biotech Clinical Research, LLC on December 9, 2021. The trademark is classified under Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Boston Biotech Clinical Research, LLC

95 Elliot St
Natick, MA 01760

Entity Type: 16

Trademark Details

Filing Date

December 9, 2021

Registration Date

November 7, 2023

Published for Opposition

August 22, 2023

Goods & Services

Business consulting and management in the field of medical and scientific research and development and clinical trials for biotechnology, pharmaceutical, and medical device companies, namely, assisting companies with developing business strategies and road maps for medical and scientific research and development; assisting companies in the nature of business advisory services in the field of business plan development for biotechnology, pharmaceutical, and medical device companies; assisting companies with trial feasibility in the nature of providing independent review of clinical trials for business purposes; assisting companies with clinical trials compliance, in the nature of business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical, and biotechnology companies to assist them with clinical research, clinical trials, and applications for drug approval; business concept development and implementation in the field of the pharmaceutical industry; business consulting and management in the field of clinical trials, namely, providing information management services; business management and development consulting services for clinical research organizations (CRO), drug manufacturers, and providing in-house and out-sourced business functions and activities, namely, outsourcing services and office administration services; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of biopharmaceutical companies to assist them with clinical research, clinical trials, and applications for drug approval in the fields of genetics, epigenetic, biologics and small molecule therapeutics, drugs, combination drug and device products; providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for medical device approval; and assisting companies with developing global regulatory approval strategies and navigating the regulatory submission and approval process, all in the nature of regulatory submission management, namely, assisting others in preparing and filing applications for new drugs with governmental regulatory bodies

Providing medical and scientific research information in the field of clinical trials; consulting services for others in the field of design, planning, and implementation project management of clinical trials

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 7, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 7, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 22, 2023 NPUB
PUBLISHED FOR OPPOSITION
Aug 22, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 2, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 18, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 18, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 18, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 18, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 18, 2023 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
May 3, 2023 GNFN
FINAL REFUSAL E-MAILED
May 3, 2023 GNFR
FINAL REFUSAL WRITTEN
May 3, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 15, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 14, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 14, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 16, 2022 GNRN
NON-FINAL ACTION E-MAILED
Nov 16, 2022 GNRT
NON-FINAL ACTION WRITTEN
Nov 16, 2022 CNRT
ASSIGNED TO EXAMINER
Sep 17, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 14, 2021 NWOS
NEW APPLICATION ENTERED
Dec 13, 2021 NWAP